[go: up one dir, main page]

IL135140A0 - Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications - Google Patents

Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Info

Publication number
IL135140A0
IL135140A0 IL13514098A IL13514098A IL135140A0 IL 135140 A0 IL135140 A0 IL 135140A0 IL 13514098 A IL13514098 A IL 13514098A IL 13514098 A IL13514098 A IL 13514098A IL 135140 A0 IL135140 A0 IL 135140A0
Authority
IL
Israel
Prior art keywords
kits
formulation
compositions
applications
preparation
Prior art date
Application number
IL13514098A
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/093,972 external-priority patent/US6825174B2/en
Application filed by Univ East Carolina filed Critical Univ East Carolina
Publication of IL135140A0 publication Critical patent/IL135140A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
IL13514098A 1997-09-17 1998-09-17 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications IL135140A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5916097P 1997-09-17 1997-09-17
US09/093,972 US6825174B2 (en) 1995-06-07 1998-06-09 Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
PCT/US1998/019419 WO1999013886A1 (en) 1997-09-17 1998-09-17 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Publications (1)

Publication Number Publication Date
IL135140A0 true IL135140A0 (en) 2001-05-20

Family

ID=26738426

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13514098A IL135140A0 (en) 1997-09-17 1998-09-17 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Country Status (8)

Country Link
EP (1) EP1019065A4 (en)
JP (1) JP2003517428A (en)
KR (1) KR20010030622A (en)
AU (1) AU752531B2 (en)
BR (1) BR9812650A (en)
CA (1) CA2304312A1 (en)
IL (1) IL135140A0 (en)
WO (1) WO1999013886A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US20040043948A1 (en) * 2001-09-24 2004-03-04 Isis Pharmaceuticals Inc. Antisense modulation of interleukin 8 expression
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030060438A1 (en) * 2000-08-18 2003-03-27 Henry James L. Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9657294B2 (en) * 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2004011613A2 (en) * 2002-07-29 2004-02-05 Epigenesis Pharmaceuticals, Inc. Composition & methods for treatment and screening
US7956176B2 (en) * 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003287169A1 (en) * 2002-10-18 2004-05-04 Genta Salus Llc Inhibitory oligonucleotides targeted to matrix metalloproteinase-9
AU2003301905A1 (en) * 2002-11-06 2004-06-03 Ludwig Institute For Cancer Research Compositions and methods for treating acute myeloid leukemia
CA2421086A1 (en) * 2003-02-28 2004-08-28 Institut Pasteur Chicken rna polymerase i promoter and its use
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
JP5314283B2 (en) 2004-10-29 2013-10-16 トピジェン・ファーマシューティカルズ・インコーポレーテッド Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
EP2316941A3 (en) * 2005-02-25 2012-03-14 Isis Pharmaceuticals, Inc. Compositions and their uses directed to IL-4R alpha
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
CN102712925B (en) * 2009-07-24 2017-10-27 库尔纳公司 Treatment of SIRTUIN (SIRT)-associated diseases by inhibiting the natural antisense transcript of SIRTUIN (SIRT)
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2015130832A1 (en) * 2014-02-25 2015-09-03 The Regents Of The University Of California Agents for enhancement of production of biofuel precursors in microalgae
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US10350307B2 (en) * 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
CA3106701A1 (en) 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
CN114007665B (en) 2019-04-11 2024-11-12 因柯利尔疗法公司 Method for improving cerebrospinal fluid and its device and system
CN110527630B (en) * 2019-05-24 2021-04-20 浙江工业大学 Aleurites lutescens mutant strain bred by ARTP mutagenesis technology and application thereof
AU2021206510A1 (en) * 2020-01-08 2022-08-04 Microvascular Therapeutics, Llc Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery
US12329930B2 (en) 2020-09-29 2025-06-17 Enclear Therapies, Inc. Subarachnoid fluid management method and system
WO2022271938A1 (en) * 2021-06-23 2022-12-29 Enclear Therapies, Inc. Method of regulating gene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210273D0 (en) * 1992-05-13 1992-07-01 Ici Plc Dna
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease

Also Published As

Publication number Publication date
EP1019065A1 (en) 2000-07-19
WO1999013886A1 (en) 1999-03-25
WO1999013886B1 (en) 1999-04-22
AU752531B2 (en) 2002-09-19
KR20010030622A (en) 2001-04-16
CA2304312A1 (en) 1999-03-25
AU9395198A (en) 1999-04-05
EP1019065A4 (en) 2002-02-20
JP2003517428A (en) 2003-05-27
BR9812650A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
IL135140A0 (en) Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
AU1581895A (en) Nucleic acid-containing composition, its preparation and use
IL123393A0 (en) Pesticide compositions comprising redispersible polymers
AU8680698A (en) Polynucleotide compositions
AU2224899A (en) Antimicrobial nail coating composition
AU2215995A (en) Freeze-dried compositions comprising rna
IL130777A (en) 3-heterocyclyl-substituted benzoyl derivatives, their preparation and compositions comprising them
AU1485997A (en) Quick-drying aqueous coating compositions
IL142736A0 (en) Transcriptional activator lec 1 nucleic acids, polypeptides and their uses
AU6018399A (en) Plant glutamine: fructose-6-phosphate amidotransferase nucleic acids
HUP0102372A3 (en) Dihydropyrimidines, preparation thereof and pharmaceutical compositions containing the same
AU5254098A (en) Conditioning shampoo compositions
AU1119399A (en) Microorganism genomics, compositions and methods related thereto
AU1383699A (en) Coating composition
AU5203098A (en) Nail enamel composition
ZA974081B (en) Nail enamel compositions.
AU6408898A (en) Antimicrobial compositions, their preparation and use
PL342045A1 (en) 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases
AU3698297A (en) Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy
EP1374894A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
AU2710400A (en) Monocyte-derived nucleic acids and related compositions and methods
AU4724799A (en) Compositions comprising endotoxin neutralizing protein and derivatives and uses thereof
HK1029522A (en) Multiple target hybridizing nucleic acids, their prepatation, compositions, formulation, kits and applications
AU1728197A (en) Lipopolyamine compound, pharmaceutical composition and nucleic acid transfer vector containing same, and preparation method
PL342944A1 (en) Nucleic acid transfer vectors, compositions containing same and uses